Key result
Anticoagulation therapy using VKA for distal DVT showed a benefit with little or no difference in major bleeding, though clinically relevant non-major bleeding increased compared to placebo.
Why the study?
The optimal treatment for distal deep vein thrombosis is not clearly established, with debate over whether to use anticoagulation or close monitoring.
Does anticoagulation therapy using VKA reduce the recurrence of VTE and DVT in people with distal deep vein thrombosis?
Meta-Analysis
Does anticoagulation therapy using VKA reduce the recurrence of VTE and DVT in people with distal deep vein thrombosis?
Anticoagulation with VKA for distal DVT appears beneficial for preventing recurrence without significantly increasing major bleeding, though it increases clinically relevant non-major bleeding.
Answers are grounded in this paper and cite their sources.
Supports VKA for distal DVT; reinforces RCT evidence with quantified recurrence benefit and bleeding trade-offs.
BACKGROUND: The treatment of distal (below the knee) deep vein thrombosis (DVT) is not clearly established. Distal DVT can either be treated with anticoagulation, or monitored with close follow-up to detect progression to the proximal veins (above the knee), which requires anticoagulation. Proponents of this monitoring strategy base their decision to withhold anticoagulation on the fact that progression is rare and most people can be spared from potential bleeding and other adverse effects of anticoagulation. OBJECTIVES: To assess the effects of different treatment interventions for people with distal (below the knee) deep vein thrombosis (DVT). SEARCH METHODS: The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 12 February 2019. We also undertook reference checking to identify additional studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) for the treatment of distal DVT. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials and extracted data. We resolved disagreements by discussion. Primary outcomes of interest were recurrence of venous thromboembolism (VTE), DVT and major bleeding and follow up ranged from three months to two years. We performed fixed-effect model meta-analyses with risk ratio (RRs) and 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE. MAIN RESULTS: = 1%; low-certainty evidence) between three months or more of treatment and six weeks of treatment. There were no reports for overall mortality or PE and major bleeding-related deaths. AUTHORS' CONCLUSIONS: Our review found a benefit for people with distal DVT treated with anticoagulation therapy using VKA with little or no difference in major bleeding events although there was an increase in clinically relevant non-major bleeding when compared to no intervention or placebo. The small number of participants in this meta-analysis and strength of evidence prompts a call for more research regarding the treatment of distal DVT. RCTs comparing different treatments and different treatment periods with placebo or compression therapy, are required.
No takes yet. Share an insight, caveat, or question.
Kirkilesis et al. (2020) conducted a meta-analysis in distal deep vein thrombosis (DVT). Anticoagulation therapy using VKA vs. no intervention or placebo was evaluated on recurrence of venous thromboembolism (VTE), DVT and major bleeding. Anticoagulation therapy using VKA for distal DVT showed a benefit with little or no difference in major bleeding, though clinically relevant non-major bleeding increased compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: